389 related articles for article (PubMed ID: 30811140)
21. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
22. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
[TBL] [Abstract][Full Text] [Related]
23. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
Strand V; Fiorentino D; Hu C; Day RM; Stevens RM; Papp KA
Health Qual Life Outcomes; 2013 May; 11():82. PubMed ID: 23663752
[TBL] [Abstract][Full Text] [Related]
24. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
25. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
Amano M; Grant A; Kerdel FA
Int J Dermatol; 2010 Aug; 49(8):950-5. PubMed ID: 21128923
[TBL] [Abstract][Full Text] [Related]
26. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
[TBL] [Abstract][Full Text] [Related]
27. Off-label studies on apremilast in dermatology: a review.
Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K
J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262
[No Abstract] [Full Text] [Related]
28. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
Pathan E; Abraham S; Van Rossen E; Withrington R; Keat A; Charles PJ; Paterson E; Chowdhury M; McClinton C; Taylor PC
Ann Rheum Dis; 2013 Sep; 72(9):1475-80. PubMed ID: 22984171
[TBL] [Abstract][Full Text] [Related]
29. One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
Lanna C; Mazzilli S; Zangrilli A; Bianchi L; Campione E
Dermatol Ther; 2019 Nov; 32(6):e13089. PubMed ID: 31577864
[TBL] [Abstract][Full Text] [Related]
30. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
[TBL] [Abstract][Full Text] [Related]
31. Real-world use of apremilast for patients with psoriasis in Japan.
Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
Ighani A; Georgakopoulos JR; Zhou LL; Walsh S; Shear N; Yeung J
J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
[TBL] [Abstract][Full Text] [Related]
35. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.
Sotiriou E; Goussi C; Lallas A; Chovarda E; Apalla Z; Lazaridou E; Ioannides D
J Drugs Dermatol; 2012 May; 11(5 Suppl):s15-20. PubMed ID: 22644772
[TBL] [Abstract][Full Text] [Related]
36. Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
Garcovich S; Giovanardi G; Malvaso D; De Simone C; Peris K
Medicine (Baltimore); 2020 Jan; 99(5):e18991. PubMed ID: 32000436
[TBL] [Abstract][Full Text] [Related]
37. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
[TBL] [Abstract][Full Text] [Related]
38. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
39. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
Volf EM; Au SC; Dumont N; Scheinman P; Gottlieb AB
J Drugs Dermatol; 2012 Mar; 11(3):341-6. PubMed ID: 22395585
[TBL] [Abstract][Full Text] [Related]
40. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
